<SEC-DOCUMENT>0001157523-21-000382.txt : 20210325
<SEC-HEADER>0001157523-21-000382.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210325090321
ACCESSION NUMBER:		0001157523-21-000382
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210325
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunoPrecise Antibodies Ltd.
		CENTRAL INDEX KEY:			0001715925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39530
		FILM NUMBER:		21770303

	BUSINESS ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
		BUSINESS PHONE:		6048060626

	MAIL ADDRESS:	
		STREET 1:		880 - 580 HORNBY STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6C3B6
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52401410.htm
<DESCRIPTION>IMMUNOPRECISE ANTIBODIES LTD. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div>&#160;<br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
      <div style="font-weight: bold;">&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: center;">For the month of March 2021</div>
      <div style="text-align: center;">&#160;</div>
      <div style="text-align: center;">Commission File Number: <font style="font-weight: bold;">001-39530</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ImmunoPrecise Antibodies Ltd.</div>
      <div style="text-align: center;">(Translation of registrant&#8217;s name into English)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8</div>
      <div style="text-align: center;">(Address of principal executive office)</div>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div style="text-align: center;"> <br>
      </div>
      <div style="text-align: center;">Form 20-F&#160; &#9744; Form 40-F&#160; &#9746;</div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div style="text-align: justify;">&#160;</div>
      <div style="text-align: justify;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Times New Roman',Times,serif;"> </font></div>
      <div style="text-align: justify;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="text-align: center;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8d22876af5434a7eb5bf18b9f1156f20">

          <tr>
            <td style="width: 11.54%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 86%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 11.54%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div><a href="a52401410_ex991.htm">99.1</a></div>
            </td>
            <td style="width: 1.54%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 86%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
              <div style="text-align: justify;"><a href="a52401410_ex991.htm">Press Release dated March 25, 2021.</a></div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="margin-top: 6pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="text-align: center; margin-top: 6pt; font-weight: bold;">SIGNATURE</div>
      <div style="text-align: center; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; text-indent: 24pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z962d9fc8d6eb4c3dbfaa4583d105034d">

          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div style="font-weight: bold;">IMMUNOPRECISE ANTIBODIES LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Date: March 25, 2021</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
              <div style="font-style: italic;">/s/ Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Lisa Helbling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
            <td style="width: 47%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd7156354878f4456a8f31f14de78cc4d">

          <tr>
            <td style="width: 100%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52401410_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.4.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div><font style="font-weight: bold;"> </font>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of
          Concern</b> </h1>
      <div class="bw-release-subhead">
        <ul style="list-style-type: disc;">
          <b>
            <li> <b>Blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action</b> </li>
            <li> <b>Binds to all tested variants of concern, likely because it targets a site other than the mutation prone Receptor Binding Domain/ACE2 binding interface</b> </li>
            <li> <b>Works synergistically with antibodies from other epitope families, making this a potentially promising component for a combination therapy</b> </li>
          </b>
        </ul>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>VICTORIA, British Columbia--(BUSINESS WIRE)--March 25, 2021--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced the
            identification of antibody 23-H7, which preclinical data obtained to date indicates provides strong, protective anti-viral effects in SARS-CoV-2 (COVID-19) infected Syrian hamsters via an uncommon mechanism of action. </p>
          <p> While 23-H7 is able to perturb the interaction between the Receptor Binding Domain (RBD) and the host receptor ACE2, its epitope is not located on the mutation prone RBD/ACE2 interface, unlike the spike protein regions targeted by current,
            commercial SARS-CoV-2 therapies. As a result, 23-H7 is anticipated to be less vulnerable to escape mutations within the spike protein/ACE2 binding interface, like escape mutation of concern E484K. In line with this, IPA demonstrated that 23-H7
            maintained binding to the full (cell-associated) spike trimer of emerging SARS-CoV-2 variants of concern B.1.1.7 (UK), B.1.351 (S. African), and P.1 (Brazilian)<b>, </b>despite published data stating that many highly neutralizing antibody
            therapies against SARS-CoV-2, as well as most convalescent sera and vaccine-induced immune sera, show reduced activity against viral variants. </p>
          <p> <b>Preclinical efficacy study</b> </p>
          <p> Notably, <i>in vivo</i> efficacy evaluation of antibody 23-H7 when administered as a passive vaccine, twenty-four hours prior to infecting Syrian hamsters with the SARS-CoV-2-D614G, resulted in undetectable replication competent virus titer
            in the lungs of four of the five animals 4 days post infection, with the remaining animal showing a replication competent viral titer barely above the lowest level of detection. As binding of this antibody to multi- and single-mutated spike
            protein trimers and fragments, respectively, appears to be unaffected, IPA anticipates that this antibody has the potential to maintain similar <i>in vivo</i> protective efficacy against corresponding viral variants. </p>
          <div> </div>
          <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
            <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <i>In vitro</i> analyses of studies conducted by IPA revealed that antibody 23-H7 can co-exist on the SARS-CoV-2 spike protein with antibodies from several other epitope families, as well as antibodies directly blocking the RBD/ACE2
            interface, and is able to work synergistically when combined with antibodies from other epitope families in (pseudo)virus neutralization assays. Therefore, IPA believes that this unique lead is a very promising component for a combination
            therapy. Apart from increasing blockade of host cell infection, applying multiple antibodies targeting different regions of the spike protein simultaneously is expected to enhance viral clearance by the host&#8217;s immune system in a coordinated
            effort. Next to the benefit of capturing multiple mechanisms of action in one therapy, IPA&#8217;s PolyTope antibody cocktail approach is also believed to reduce the risk of mutagenic escape, and thereby expectedly increases its sustainability. </p>
          <p> &#8220;The identification of IPA&#8217;s genetically diverse set of therapeutic antibodies with multiple mechanisms of action and broad epitope coverage is a reflection of our proprietary technology&#8217;s ability to deeply mine diverse human antibody
            repertoires, which ultimately enabled the discovery of this exciting, unique antibody, 23-H7,&#8221; stated Ilse Roodink, IPA&#8217;s Global COVID-19 Program Director. &#8220;This finding is also a reflection of our overall commitment to quality science and
            meaningful, translational outcomes.&#8221; </p>
          <p> <b>About IPA&#8217;s PolyTope Platform. </b> </p>
          <p> IPA&#8217;s SARS-CoV-2 PolyTope monoclonal therapies are designed to protect against mutagenic escape with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2. They are created with the goal of sustainable efficacy in the
            face of an evolving virus, combining extensively characterized, potently neutralizing, synergistic antibodies exhibiting richly diverse epitope coverage. </p>
          <div> </div>
          <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
            <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>About ImmunoPrecise Antibodies Ltd.</b> </p>
          <p> IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The
            Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the
            Company&#8217;s therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes. For further information,
            visit www.immunoprecise.com or contact solutions@immunoprecise.com. </p>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <p> <b>Forward Looking Information</b> </p>
          <div> </div>
          <p> This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as &#8220;potential&#8221;,
            &#8220;plans&#8221;, &#8220;expects&#8221; or &#8220;does not expect&#8221;, &#8220;is expected&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221; or &#8220;does not anticipate&#8221;, or &#8220;believes&#8221;, or variations of such words and phrases or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;,
            &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements regarding the potential of IPA&#8217;s antibody 23-H7 to bind to SARS-CoV-2/COVID-19
            variants of concern, to retain efficacy <i>in vivo </i>against viral variants, and to be suitable for use in combination with other antibodies and of antibody 23-H7 and IPA&#8217;s PolyTope antibody cocktail to enhance viral clearance and risk of
            mutagenic escape. In respect of the forward-looking information contained herein, the Company has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. </p>
          <p> Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or
            achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, 23-H7 and IPA&#8217;s PolyTope antibody
            cocktails have not yet been tested in humans and the Company may not be successful in developing antibody 23-H7 or its PolyTope antibody cocktail or other vaccines or therapeutics against COVID-19 through the successful and timely completion of
            preclinical assays, studies and clinical trials, or may not receive all regulatory approvals to commence and then continue clinical trials of its products, and,<u> t</u>o be successful in partnering or commercializing its products related to
            COVID-19, the coverage and applicability of the Company&#8217;s intellectual property rights to its antibodies, as well as those risks discussed in the Company&#8217;s Annual Information Form dated November 16, 2020 (which may be viewed on the Company&#8217;s
            profile at www.sedar.com) and the Company&#8217;s Form 40-F dated December 28, 2020 (which may be viewed on the Company&#8217;s profile at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the
            forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place
            undue reliance on forward-looking information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The
            Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. Neither the TSX Venture
            Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Investors: Fr&#233;d&#233;ric Chabot, Phone: 1-438-863-7071, <br>
            Email: fchabot@immunoprecise.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
